These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9359506)

  • 21. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
    van den Heuvel-Eibrink MM; van der Holt B; Burnett AK; Knauf WU; Fey MF; Verhoef GE; Vellenga E; Ossenkoppele GJ; Löwenberg B; Sonneveld P
    Ann Hematol; 2007 May; 86(5):329-37. PubMed ID: 17340137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Childhood acute myelogenous leukaemia: association between PRAME, apoptosis- and MDR-related gene expression.
    Goellner S; Steinbach D; Schenk T; Gruhn B; Zintl F; Ramsay E; Saluz HP
    Eur J Cancer; 2006 Nov; 42(16):2807-14. PubMed ID: 16978861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional expression of MDR-1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics.
    Martínez A; San Miguel JF; Valverde B; Bárez A; Moro MJ; García-Marcos MA; Pérez-Simón JA; Vidriales B; Orfao A
    Ann Hematol; 1997 Sep; 75(3):81-6. PubMed ID: 9368475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
    Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
    Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance factors in acute myeloid leukemia: a comparative analysis.
    Filipits M; Stranzl T; Pohl G; Heinzl H; Jäger U; Geissler K; Fonatsch C; Haas OA; Lechner K; Pirker R
    Leukemia; 2000 Jan; 14(1):68-76. PubMed ID: 10637479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay.
    Lamy T; Drenou B; Grulois I; Fardel O; Jacquelinet C; Goasguen J; Dauriac C; Amiot L; Bernard M; Fauchet R
    Leukemia; 1995 Sep; 9(9):1549-55. PubMed ID: 7658724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
    Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
    Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia.
    Del Poeta G; Venditti A; Stasi R; Aronica G; Cox MC; Buccisano F; Tamburini A; Bruno A; Maurillo L; Battaglia A; Suppo G; Epiceno AM; Del Moro B; Masi M; Amadori S; Papa G
    Leuk Res; 1999 May; 23(5):451-65. PubMed ID: 10374859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
    Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
    Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
    Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
    Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
    Bernstein SH; Brunetto VL; Davey FR; Wurster-Hill D; Mayer RJ; Stone RM; Schiffer CA; Bloomfield CD
    J Clin Oncol; 1996 Sep; 14(9):2486-94. PubMed ID: 8823327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-glycoprotein expression in de novo acute myeloid leukemia.
    Del Poeta G; Venditti A; Aronica G; Stasi R; Cox MC; Buccisano F; Bruno A; Tamburini A; Suppo G; Simone MD; Epiceno AM; Del Moro B; Masi M; Papa G; Amadori S
    Leuk Lymphoma; 1997 Oct; 27(3-4):257-74. PubMed ID: 9402325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
    Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
    Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells.
    Suárez L; Vidriales MB; Moreno MJ; López A; García-Laraña J; Pérez-López C; Tormo M; Lavilla E; López-Berges MC; de Santiago M; San Miguel JF; Orfao A;
    Haematologica; 2005 Jan; 90(1):54-9. PubMed ID: 15642669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression.
    Legrand O; Perrot JY; Simonin G; Baudard M; Cadiou M; Blanc C; Ramond S; Viguié F; Marie JP; Zittoun R
    Br J Haematol; 1998 Jan; 100(1):147-55. PubMed ID: 9450804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leukaemia cell drug resistance and prognostic factors in AML.
    Nørgaard JM; Olesen G; Kristensen JS; Pedersen B; Hokland P
    Eur J Haematol; 1999 Oct; 63(4):219-24. PubMed ID: 10530409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia.
    Chisini M; Stefanizzi C; Ceglie T; Raponi S; Vozella F; Colafigli G; Salaroli A; D'Angiò M; Mancini M; Diverio D; Breccia M; Mancini F; Minotti C; Trisolini S; Capria S; Testi AM; Guarini A; Latagliata R; De Propris MS; Foà R
    Hematol Oncol; 2017 Dec; 35(4):804-809. PubMed ID: 27400753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy.
    Kasimir-Bauer S; Ottinger H; Meusers P; Beelen DW; Brittinger G; Seeber S; Scheulen ME
    Exp Hematol; 1998 Nov; 26(12):1111-7. PubMed ID: 9808049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome.
    Schaich M; Harbich-Brutscher E; Pascheberg U; Mohr B; Soucek S; Ehninger G; Illmer T
    Haematologica; 2002 May; 87(5):455-64. PubMed ID: 12010657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.